To Evaluate Interventions That Address Drivers Of Health, Look Beyond ROI - Health Affairs

What every law enforcement agency needs to knowHighlightsOfficers are already using AI faster than most agencies have policies to guide it. Consumer AI tools skip citations and audit trails, creating real risk for evidence and cases. A structured framework — covering data sourcing, courtroom defensibility, ROI, and documentation — helps agencies choose AI tools that hold up under scrutiny. Artificial intelligence isn’t a future consideration for law enforcement anymore. It’s already inside the tools officers use every day to draw insights from public records. A recent Police1 webcast in partnership with Thomson Reuters “How to Evaluate AI Technology for Investigations” brought together Edgar Gallardo and Michael Murphy, both former officers now working for Thomson Reuters, along with Andrew Pellington, Senior Director of Product Marketing for Thomson Reuters, to unpack one practical question. How should agencies vet an AI tool before it touches an investigation? Poll results from the session tell part of the story. 72% of attendees said their agency is already using or evaluating AI tools, and 87% said they believe AI is helping public safety.

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.

European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.